Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNASDAQ:BEAMNASDAQ:MREONASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.72-0.3%$13.96$7.86▼$17.75$1.65B1.772.20 million shs778,148 shsBEAMBeam Therapeutics$20.02+0.7%$17.64$13.53▼$35.25$2.01B2.071.51 million shs1.36 million shsMREOMereo BioPharma Group$2.88+0.2%$2.55$1.58▼$5.02$456.33M0.461.09 million shs799,203 shsSRPTSarepta Therapeutics$18.22+0.1%$35.34$16.88▼$154.90$1.79B0.452.19 million shs2.48 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%-0.18%+1.52%-6.89%+42.86%BEAMBeam Therapeutics0.00%+19.17%+17.76%+31.11%-14.74%MREOMereo BioPharma Group0.00%+8.08%+16.87%+44.47%-19.92%SRPTSarepta Therapeutics0.00%+6.46%-53.55%-66.53%-88.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.0604 of 5 stars3.41.00.00.02.21.70.6BEAMBeam Therapeutics2.5203 of 5 stars3.51.00.00.02.62.50.6MREOMereo BioPharma Group1.7959 of 5 stars3.63.00.00.00.01.70.0SRPTSarepta Therapeutics4.7382 of 5 stars4.22.00.04.22.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8037.08% UpsideBEAMBeam Therapeutics 3.00Buy$48.75143.51% UpsideMREOMereo BioPharma Group 3.20Buy$7.60164.35% UpsideSRPTSarepta Therapeutics 2.44Hold$60.88234.20% UpsideCurrent Analyst Ratings BreakdownLatest MREO, BEAM, SRPT, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell6/20/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.006/20/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform6/18/2025SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.006/18/2025SRPTSarepta TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$24.006/17/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$50.00 ➝ $25.006/17/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$29.006/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.006/17/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.006/17/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$89.00 ➝ $29.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M8.32N/AN/A$1.35 per share10.16BEAMBeam Therapeutics$63.58M31.66N/AN/A$8.86 per share2.26MREOMereo BioPharma GroupN/AN/AN/AN/A$0.39 per shareN/ASRPTSarepta Therapeutics$1.90B0.94$2.43 per share7.49$15.99 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.66N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)Latest MREO, BEAM, SRPT, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABEAMBeam Therapeutics$0.904.50%N/AN/A N/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.753.553.37BEAMBeam TherapeuticsN/A8.818.81MREOMereo BioPharma GroupN/A8.928.92SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABEAMBeam Therapeutics99.68%MREOMereo BioPharma Group62.83%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BEAMBeam Therapeutics3.50%MREOMereo BioPharma Group5.50%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableBEAMBeam Therapeutics510100.56 million97.04 millionOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableMREO, BEAM, SRPT, and ARQT HeadlinesRecent News About These CompaniesSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsJuly 6 at 8:15 AM | globenewswire.comINVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, ...July 5 at 6:27 PM | gurufocus.comROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJuly 5 at 2:31 PM | markets.businessinsider.comINVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 5 at 11:40 AM | globenewswire.comBraun Stacey Associates Inc. Has $4.20 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)July 5 at 8:41 AM | marketbeat.comSRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, ...July 4 at 4:31 PM | gurufocus.comSRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 4 at 4:00 PM | globenewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. ...July 4 at 9:12 AM | gurufocus.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPTJuly 4 at 8:23 AM | globenewswire.comRobbins LLP Files Class Action Against Sarepta Therapeutics Over ELEVIDYS DeathsJuly 4 at 6:48 AM | lawyer-monthly.comLSarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the ...July 3 at 8:09 PM | gurufocus.comSarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action LawsuitJuly 3 at 7:33 PM | globenewswire.comSarepta Therapeutics, Inc. Sued for Securities Law Violations -- Investors Should Contact Levi ...July 3 at 5:13 PM | gurufocus.comSarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPTJuly 3 at 4:27 PM | globenewswire.comSRPT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action LawsuitJuly 3 at 10:50 AM | businesswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPTJuly 3 at 9:00 AM | prnewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsJuly 3 at 8:01 AM | prnewswire.comShareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPTJuly 2, 2025 | globenewswire.comSRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud LawsuitJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)July 2, 2025 | globenewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsJuly 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMREO, BEAM, SRPT, and ARQT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.72 -0.05 (-0.33%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$13.72 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Beam Therapeutics NASDAQ:BEAM$20.02 +0.14 (+0.70%) Closing price 07/3/2025 03:12 PM EasternExtended Trading$20.19 +0.17 (+0.84%) As of 07/3/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Mereo BioPharma Group NASDAQ:MREO$2.88 +0.01 (+0.17%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$2.88 0.00 (0.00%) As of 07/3/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Sarepta Therapeutics NASDAQ:SRPT$18.22 +0.03 (+0.14%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$18.22 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
